Final PFS2 analysis shows sustained PFS benefit of maintenance olaparib in ovarian cancer
04 Nov 2020
bởiAudrey Abella
The initial progression-free survival (PFS) improvement obtained with the addition of olaparib to bevacizumab was sustained beyond first progression, as reflected by the significant PFS2 benefit in women with newly diagnosed, advanced high‐grade ovarian cancer, according to the final PFS2 analysis of the phase III PAOLA-1*/ENGOT-ov25 trial.
